Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: Comparison with fenofibrate

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 9, 1997, Pages 1793-1799

  Ooi, Teik C ^a   Heinonen, Therese ^b   Alaupovic, Petar ^c   Davignon, Jean ^d   Leiter, Lawrence ^e   Lupien, Paul J ^f   Sniderman, Allan D ^g   Tan, Meng H ^h   Tremblay, Gerald ⁱ   Sorisky, Alexander ^a   Shurzinske, Linda ^b   Black, Donald M ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b PFIZER INC   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e St Michaels Health Centre   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g ROYAL VICTORIA HOSPITAL   (Canada)

^h Camp Hill Hospital   (Canada)

ⁱ CHICOUTIMI HOSPITAL   (Canada)

Author keywords

Atorvastatin; Combined hyperlipidemia; Fenofibrate; Hydroxy methylglutaryl coenzyme A reductase inhibitor

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DYSPEPSIA; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 16944366095     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.9.1793     Document Type: Article

References (19)

1. Consensus Conference. Lowering blood cholesterol to prevent heart disease. JAMA. 1985;253:2080-2086.
2. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA. 1987;257:2176-2180.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb. 1993;13:427-434.
5. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
6. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter and risk of myocardial infarction. JAMA. 1996;276:882-888.
7. Williams RR, Hopkins PN, Hunt SC, Wu LL, Hasstedt SJ, Lalouel JM, Ash KO, Stults BM, Kuida H. Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah. Arch Intern Med. 1990;150:582-588.
8. Guidelines of the European Atherosclerosis Society, A Desktop Guide to the Management of Risk Factors for Coronary Heart Disease, 1993.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
10. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 1988;109:25-32.
11. Black D. Atorvastatin. A Step Ahead for HMG-CoA Reductase Inhibitors. In: Woodford FP, Davignon J, Sniderman A, eds. Atherosclerosis X. New York: Elsevier Science; 1995:307-310.
12. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypcrcholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vase Biol. 1995;15:678-682.
13. Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, Kivel F, Black DM. Atorvastatin, a new HMG-CoA reductase inhibitor as mono-therapy and combined with colestipol. J Cardiovasc Phannacol Therapeut. 1996;1:117-122.
14. Best JD, Nicholson GC, O'Neal DN, Kotowicz M, Sanders K. Atorvastatin and simvastatin reduce elevated cholesterol in noninsulin dependent diabetes. Diab Nutr Metab. 1996;9:74-80.
15. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128-133.
16. Durrington PN, Hunt L, Ishoha M, Kane J, Stephens WP. Serum apolipoproteins AI & B and lipoproteins in middle-aged men with and without previous myocardial infarction. Br Heart J. 1986;56:206-212.
17. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, Despres JP. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 1996;94:237-278.
18. Sniderman AD, Cianflone K. Measurement of apoproteins: Time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias [editorial; comment]. Clin Chem. 1996;42:489-491.
19. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 1994;343:75-79.